Tecentriq (Atezolizumab) vs Gavreto (pralsetinib)

Tecentriq (atezolizumab) is an immune checkpoint inhibitor specifically targeting the PD-L1 protein and is used for various types of cancer, including non-small cell lung cancer (NSCLC), urothelial carcinoma, and triple-negative breast cancer. Gavreto (pralsetinib) is a targeted therapy known as a RET kinase inhibitor, used for treating NSCLC with RET gene alterations and certain types of thyroid cancers. When deciding between Tecentriq and Gavreto, it is crucial to consider the specific type of cancer, its molecular profile, and the presence of specific genetic markers, as Gavreto is effective in cancers with RET mutations, while Tecentriq is more broadly used in cancers expressing the PD-L1 protein.

Difference between Tecentriq and Gavreto

Metric	Tecentriq (Atezolizumab)	Gavreto (pralsetinib)
Generic name	Atezolizumab	Pralsetinib
Indications	Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer	Non-small cell lung cancer, RET fusion-positive thyroid cancer
Mechanism of action	PD-L1 inhibitor	RET kinase inhibitor
Brand names	Tecentriq	Gavreto
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, nausea, decreased appetite, urinary tract infection, fever, etc.	Constipation, hypertension, fatigue, musculoskeletal pain, etc.
Contraindications	None known beyond hypersensitivity to atezolizumab or its excipients	None known beyond hypersensitivity to pralsetinib or its excipients
Drug class	Monoclonal antibody, Immune checkpoint inhibitor	Tyrosine kinase inhibitor
Manufacturer	Genentech (Roche)	Blueprint Medicines Corporation

Efficacy

Tecentriq (Atezolizumab) Efficacy in Lung Cancer

Tecentriq (Atezolizumab) is an immunotherapy drug classified as a programmed death-ligand 1 (PD-L1) inhibitor. It has been approved for the treatment of certain types of lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In NSCLC, Tecentriq has shown efficacy as a monotherapy in treating patients with metastatic disease who have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations. When used in combination with chemotherapy, Tecentriq has improved survival outcomes in patients with metastatic non-squamous NSCLC, irrespective of PD-L1 expression. For extensive-stage SCLC, Tecentriq in combination with chemotherapy has demonstrated a significant improvement in overall survival compared to chemotherapy alone.

Gavreto (Pralsetinib) Efficacy in Lung Cancer

Gavreto (Pralsetinib) is a targeted therapy known as a RET kinase inhibitor, which has been approved for the treatment of adults with metastatic RET fusion-positive NSCLC. The efficacy of Gavreto in lung cancer was demonstrated in a series of clinical trials where patients with RET fusion-positive NSCLC experienced significant anti-tumor activity. The response rate was notable, and many patients achieved partial or complete responses to the treatment. The duration of response also supported the use of Gavreto in this patient population, with many responses being durable.

Comparative Efficacy in Lung Cancer Treatment

While both Tecentriq and Gavreto have shown efficacy in treating lung cancer, their use is dependent on different biomarkers and genetic profiles of the tumor. Tecentriq's effectiveness is closely associated with the expression of PD-L1 and is used across a broader range of lung cancer patients, while Gavreto is specifically for patients with RET fusion-positive NSCLC. The choice of treatment depends on the molecular characteristics of the cancer, and therefore, biomarker testing is essential before initiating therapy with either of these medications.

Conclusion

In conclusion, Tecentriq and Gavreto have both expanded the treatment landscape for lung cancer, offering hope for improved outcomes in specific patient populations. Tecentriq's role in immunotherapy and its ability to improve survival in NSCLC and SCLC, as well as Gavreto's targeted approach for RET fusion-positive NSCLC, highlight the importance of personalized medicine in oncology. Ongoing research and clinical trials continue to refine the use of these drugs and further elucidate their efficacy in lung cancer treatment.

Regulatory Agency Approvals

Tecentriq

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Gavreto

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Tecentriq or Gavreto today

If Tecentriq or Gavreto are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Tecentriq

Buy Gavreto

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: